Tech24 Deals Web Search

Search results

1. Results from the Tech24 Deals Content Network

2. Glucerna - Wikipedia

   en.wikipedia.org/wiki/Glucerna

   Glucerna is the brand name of a family of tube feeding formula, bottled or canned shakes, and snack bars manufactured by Abbott Laboratories. [1] It was introduced to the public in 1989. [ 2 ] These medical nutritional products are meant for people with diabetes and are promoted for their ability to satisfy hunger without causing rapid ...

3. Does Medicare cover Ozempic? Yes — but it depends on your Rx

   www.aol.com/finance/does-medicare-cover-ozempic...

   Over 38 million Americans have diabetes, according to the Centers for Disease Control and Prevention (CDC), and more than 90% of these cases are Type 2 diabetes. Managing Type 2 diabetes requires ...

4. Intravenous sugar solution - Wikipedia

   en.wikipedia.org/wiki/Intravenous_sugar_solution

   UNII. 5SL0G7R0OK. Intravenous sugar solution, also known as dextrose solution, is a mixture of dextrose (glucose) and water. [ 1] It is used to treat low blood sugar or water loss without electrolyte loss. [ 2] Water loss without electrolyte loss may occur in fever, hyperthyroidism, high blood calcium, or diabetes insipidus. [ 2]

5. Hypoglycemia - Wikipedia

   en.wikipedia.org/wiki/Hypoglycemia

   Hypoglycemia, also called low blood sugar, is a fall in blood sugar to levels below normal, typically below 70 mg/dL (3.9 mmol/L). [ 1][ 3] Whipple's triad is used to properly identify hypoglycemic episodes. [ 2] It is defined as blood glucose below 70 mg/dL (3.9 mmol/L), symptoms associated with hypoglycemia, and resolution of symptoms when ...

6. US FDA says two more doses of Novo Nordisk's weight ... - AOL

   www.aol.com/news/us-fda-says-two-more-213745011.html

   Several doses of Novo's GLP-1 therapies such as diabetes drug Ozempic and Wegovy, both chemically known as semaglutide, have been on the U.S. health regulator's shortage list since early 2022.

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.